(Q36543189)

English

Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma.

scientific article published on June 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859575%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

Europe PubMed Central

Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859575%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Kesava Reddy

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859575%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

language of work or name

0 references

publication date

1 June 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859575%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Clinical Genitourinary Cancer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859575%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859575%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

23-25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859575%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859575%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1558-7673%2811%2970151-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1558-7673%2811%2970151-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

1 reference

https://api.crossref.org/works/10.1016%2FS1558-7673%2811%2970151-3

7 January 2021

based on heuristic

inferred from DOI database lookup

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1558-7673%2811%2970151-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1558-7673(11)70151-3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859575%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859575%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36543189&oldid=1517947025"